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Abstract: Testing of symptomatic persons for infection with severe 
acute respiratory syndrome coronavirus-2 is occurring worldwide. 
We propose two types of case–control studies that can be carried out 
jointly in test settings for symptomatic persons. The first, the test-
negative case–control design (TND) is the easiest to implement; it 
only requires collecting information about potential risk factors for 
Coronavirus Disease 2019 (COVID-19) from the tested symptomatic 
persons. The second, standard case–control studies with population 
controls, requires the collection of data on one or more population 
controls for each person who is tested in the test facilities, so that 
test-positives and test-negatives can each be compared with popula-
tion controls. The TND will detect differences in risk factors between 
symptomatic persons who have COVID-19 (test-positives) and those 
who have other respiratory infections (test-negatives). However, risk 
factors with effect sizes of equal magnitude for both COVID-19 
and other respiratory infections will not be identified by the TND. 
Therefore, we discuss how to add population controls to compare 
with the test-positives and the test-negatives, yielding two additional 
case–control studies. We describe two options for population control 
groups: one composed of accompanying persons to the test facilities, 
the other drawn from existing country-wide healthcare databases. We 
also describe other possibilities for population controls. Combining 
the TND with population controls yields a triangulation approach 
that distinguishes between exposures that are risk factors for both 
COVID-19 and other respiratory infections, and exposures that are 
risk factors for just COVID-19. This combined design can be applied 
to future epidemics, but also to study causes of nonepidemic disease.
Keywords: Case–control studies; COVID-19; Epidemiologic meth-
ods; Population controls; SARS-CoV-2; Test-negative design
(Epidemiology 2020;31: 836–843)
Widespread testing is essential for monitoring the Coro-navirus 2019 Disease (COVID-19) pandemic.1, 2 Most 
countries are focusing on testing persons with symptoms to 
identify patients with Severe Acute Respiratory Syndrome Co-
ronavirus-2 (SARS-CoV-2) infections. Ideally, this should be 
coupled with random/representative population testing to fol-
low the epidemic in the population.3 However, there is much 
that can be learnt about the causes of COVID-19, even if only 
symptomatic people are tested. Still more may be learnt by 
conducting formal test-negative design studies, with additional 
population controls, thus yielding three linked case–control 
studies. In this article, we describe how these combined study 
designs can enhance understanding of risk factors for symp-
tomatic SARS-CoV-2 infection in the COVID-19 pandemic.
Essence of the Test-negative Case–Control 
Design
Test-negative case–control studies4–9 are based on per-
sons who undergo testing because they present with signs and 
symptoms of a particular disease. The cases are those who test 
positive for the disease, and the controls are those who test 
negative—the latter will have another reason for their signs 
and symptoms, most likely another disease.8 These “cases” 
and “controls” usually come from one geographic popula-
tion, although not everyone in a particular area may present 
for testing (and some people may come from outside the area).
Test-negative case–control designs (TNDs) involve 
comparing the odds of a given intervention (e.g., vaccine re-
ceipt) or a given risk factor (e.g., oral contraceptives) among 
symptomatic persons who test positive compared to those who 
test negative. Given assumptions described in the literature,8 
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it can produce effect estimates (odds ratios) that are gener-
alizable to the general population (See eAppendix A; http://
links.lww.com/EDE/B716 for more detail). The approach is 
most commonly known for its use in assessing vaccine effec-
tiveness,4 but has also been applied to study risk factors for 
antibiotic resistance,5, 10 and to estimate risk factors in circum-
stances in which diagnostic bias was suspected, for example, 
in studies on oral contraceptives and venous thrombosis, and 
on aspirin use and Reye syndrome.8
Test-negative designs allow us to obtain quick answers 
to important questions. Additionally, by design, they protect 
against some forms of bias which are otherwise difficult to con-
trol. People who are tested for a disease will not be a represen-
tative of all those who have the disease (unless everyone in the 
population is tested)—usually, they are more likely to have se-
vere symptoms, and more likely to seek medical help. This help-
seeking behavior is affected by many factors such as age, gender, 
socioeconomic status, access to healthcare, proximity to testing 
facilities, severity of symptoms, personality, and insurance cov-
erage. In a test-negative design, the same selective forces that 
lead individuals to be tested will operate on both those who test 
positive and those who test negative. There is a substantial litera-
ture on this study design,4–9 and it is generally agreed that it can 
produce valid effect estimates under the assumption of similar 
selection pressures for the test-positives and the test-negatives.
Reasons for Considering the Test-negative 
Case–Control Design in the Coronavirus 2019 
Pandemic
Insights into risk factors for COVID-19 can be gained 
by collecting the same information on symptomatic individu-
als who test positive and those who test negative, that is, by 
performing a test-negative case–control study. Because the 
test-negatives belong to the same population (i.e., people who 
would come for testing if they had symptoms of COVID-19) 
as the test-positives, this may give timely and locally relevant 
insight into the causes of SARS-CoV-2 infection in different 
communities (urban and rural), in communities with many 
cases, or communities with few cases.
Direct comparisons of test-positives to test-negatives 
(comparison of TND in Figures 1 and 2) can yield insight 
into specific risk factors for becoming infected and sympto-
matic with SARS-CoV-2 (i.e., having COVID-19); these may 
include age, sex, race/ethnicity, socioeconomic factors (e.g., 
income, education), occupational exposures (e.g.. healthcare 
workers performing aerosol-generating procedures, delivery 
drivers, teachers), contact patterns (e.g.. household expo-
sure to confirmed case, crowding, travel histories, childcare 
responsibilities), geographic residence (e.g.. urban vs. rural), 
behavioral factors (e.g., shopping locations and smoking), 
medical risk factors (e.g., immunodeficiency), and genetic 
factors (from the swabs or blood sample taken for viral diag-
nosis, which will also contain human cells).
Some of this information might already be routinely col-
lected. If a sufficient number of test sites test large numbers of 
people, different types of additional information may be asked 
at different testing sites, so as not to burden the test sites and 
to be able to adapt questionnaires to evolving questions. Some 
risk factors may be immediately important for local decisions, 
others more widely or more theoretically. The data can be ana-
lyzed like any other case–control study, although considera-
tion should be given to assessing possible interpretation issues 
arising because both the cases and controls are drawn from a 
subgroup of the general population (see also eAppendix A; 
http://links.lww.com/EDE/B716).8
An interesting variant might be to study risk factors for 
antibody seroprevalence (instead of new infections), which is 
an approach that investigates the cumulative risk of infection 
rather than incident infection. Some of its uses are discussed 
below.
Critical Reflections on the Interpretation 
and Feasibility of the TND in the COVID-19 
Pandemic
The TND involves a comparison between persons who 
test positive for SARS-CoV-2 and persons who test negative 
but who have similar signs and symptoms. The test-negatives 
will have another reason for their similar signs and symptoms; 
most likely they will have another viral respiratory infection. 
Some exposures (e.g., overcrowding) will increase the risks 
of both COVID-19 and other respiratory infections. Thus, the 
TND can only identify those risk factors that are either to-
tally distinct or clearly different in magnitude from the risk 
factors of illnesses that manifest with similar symptoms. For 
example, if living in crowded conditions equally increases the 
risks of both COVID-19 and other respiratory infections, then 
the proportions living in crowded conditions would be similar 
in the test-positives and the test-negatives. On the other hand, 
if male sex was a risk factor for COVID-19, but not for other 
respiratory infections, then more of the test-positives than the 
test-negatives would be male.
A second concern is about the sensitivity and speci-
ficity of the test. Although reverse transcriptase-polymerase 
chain reaction (RT-PCR) testing has a high specificity for 
SARS-CoV-2, the sensitivity can vary in relation to timing 
of symptom onset,11, 12 the bodily fluid tested,13 and the assay 
used.14 There will be misclassification of cases and controls. 
This can be expected to be “nondifferential” (whether the test 
works correctly on a particular person is unrelated to exposures 
such as crowding). Such nondifferential misclassification of 
exposure or disease is a known problem in case–control stud-
ies, and it usually results in bias of the effect estimate towards 
the null (an underestimation of effects). However, there is a 
major difference between the usual case–control study and the 
TND. In the standard population-based case–control study, the 
false-negatives remain part of the source population, and only 
a (small) fraction of them will be sampled and end up in the 
control group. In contrast, in the TND, it is certain that at a 
particular test site, all false-negatives will be included in the 
control group (the test negatives); similarly, all false-positives 
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will be included in the case group—since all persons tested 
at the test site will be in the study. This may lead to stronger 
misclassification which has most consequences in situations 
wherein the proportion of COVID-19 relative to other respi-
ratory disease among the persons tested is either very high or 
very low. There is an extensive literature on sensitivity anal-
ysis for standard case–control studies,15, 16 which essentially 
involves making assumptions about how large this misclas-
sification would be, and these methods can be adapted to the 
TND situation. See eAppendix B; http://links.lww.com/EDE/
B716 for further details.
An additional reflection is about seasonality; it is not 
known at the time of writing how the incidence of SARS-
CoV-2 infections over the calendar year will evolve. There is 
the possibility that other respiratory viruses such as influenza 
might disappear during summer,11 whereas the SARS-CoV-2 
may continue to circulate; in the extreme, there may not be 
sufficient test-negative controls.
In the earliest phases of the COVID-19 epidemic, test-
ing for acute infection may not have been done. The above-
mentioned variant of a TND on seroprevalence of antibodies 
may be a solution. For example, in a hospital-based setting, se-
rologic testing of healthcare workers for antibodies specific to 
SARS-CoV-2 may yield insights into exposure risks that could 
have been missed due to the initial lack of testing for acute in-
fection. Of course, this will miss persons who did not survive.
As the epidemic progresses, risk factors for having 
had the infection might become negative risk factors for new 
infections. For example, bus drivers may have been frequently 
infected early on; if these infections conferred sufficiently 
strong immunity, bus drivers may turn up later in the epidemic 
mainly as seemingly test-negatives for acute SARS-CoV-2 in-
fection when having signs and symptoms of respiratory di-
sease (from another virus). In addition, measures might have 
been taken to shield bus drivers (passengers only entering via 
rear doors; obligatory unoccupied seats). While this muddles 
the estimates of risk factors, the immunity conferred by ear-
lier infection as well as the preventive measures taken earlier 
are worthwhile goals of a TND study. This paradox ideally 
requires investigating the evolution of the magnitude of the 
risk factor associations over the course of the epidemic, with 
additional background knowledge beyond the data; as a min-
imum we need to look separately at the upward and down-
ward phases of the epidemic curve. To verify a potential role 
of immunity in an epidemic, subsamples of test-positives and 
test-negatives for acute infection might be tested for SARS-
CoV-2 antibodies. 
Adding Standard Case–Control Studies with a 
Control Group Representing the Underlying 
Population
As noted, a TND can potentially identify risk factors for 
COVID-19 that differ from those for other respiratory infec-
tions, either in kind or in magnitude, but will not identify risk 
factors that the test-positives and test-negatives have in com-
mon. On the other hand, comparing test-positives with general 
population controls will tell us about risk factors for COVID-19, 
but does not tell us which factor is specific for SARS-CoV-2 
infections rather than respiratory infections in general. Thus, 
the ideal situation is to also have a comparison of the test-
negatives with the general population. This strategy has al-
ready been applied as an extension of TNDs of antibiotic 
resistance.5, 10
Below, we outline two different strategies to obtain pop-
ulation controls: first, the use of friends or household mem-
bers accompanying the case as matched controls, and second 
the use of a random sample from general population databases 
with healthcare and other registered information from that 
population. In a separate section, we will briefly discuss other 
possibilities for choosing controls that might be more useful 
FIGURE 1. Test-negative design and case-control 
studies with accompanying persons.
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in a diversity of situations. First, we discuss the benefits of 
population controls.
Benefits of Added Population Controls in 
Separate Case–Control Studies with Test-
positives and  
Test-negatives
The importance of having population controls can be 
seen from Figures 1 and 2, which, respectively, refer to the 
situation with accompanying persons as controls, and to the 
more general situation of population controls. A comparison 
of the findings from the TND with a case–control compar-
ison of the test-positives and their population controls (CC-
POS comparison), and a separate comparison of test-negatives 
with the population (CC-NEG comparison), will enable us to 
assess which risk factors are specific to COVID-19 and which 
are risk factors for all respiratory infections (including SARS-
CoV-2) in general. If these studies were all perfect, one would 
be able to calculate the results of any one contrast from the 
two others, for example, the results of comparison CC-POS 
should logically follow from combining the results of the 
TND comparison and comparison CC-NEG (if the odds ratio 
for male sex is 1.0 in the TND, but is 2.0 in comparison CC-
NEG, then it also should be 2.0 in comparison CC-POS). In 
reality, there might be differences due to sampling and/or un-
known selection biases. Thus, although it would be sufficient 
in theory to only conduct the TND and comparison CC-POS, 
it remains valuable to conduct also comparison CC-NEG. This 
enables “triangulation”17 with information about differences 
in risk factors between symptomatic test-positives and test-
negatives, and two case–control studies of test-positives and 
test-negatives with their population controls.
Accompanying Persons as a Control Group
Symptomatic persons who go for SARS-CoV-2 testing 
may be accompanied by other persons, for example, house-
hold members, relatives, or friends. Thus, it may be expe-
dient to ask an accompanying person to volunteer the same 
information (e.g., completing a questionnaire) at the time 
of testing the person with symptoms—this may be done be-
fore the test result is known. These persons are members of 
the source population which generated the cases and should 
not have COVID-19 symptoms. Note that for this design, it 
is not necessary to carry out the test on the accompanying 
person.
For both the test-positives (COVID-19 cases) and the 
test-negatives (controls with other respiratory infections), the 
accompanying person can be seen as a matched population 
control. Such approaches have been widely used in epidemi-
ology, and the strengths and weaknesses have been extensively 
discussed.18, 19 Briefly, using friends, siblings, or spouses as 
matched population controls has the advantage of logistic 
convenience, and may indirectly match for various risk fac-
tors (e.g., socioeconomic status, availability of healthcare, 
health seeking behavior). As with any other pair-matched 
case–control study, this necessitates a pair-matched analysis. 
Essentially, the matched analysis focuses on the subgroup of 
case–control pairs where the case and control differ with re-
spect to the exposure under study: a pair-matched analysis is 
an analysis of the differences that remain between cases and 
their controls despite them being made in effect more equal 
by the matching.
This strategy leads to the case–control comparisons rep-
resented in Figure 1: test-positives with their accompanying 
persons (CC-POS comparison), and test-negatives with their 
accompanying persons (CC-NEG comparison). Comparison 
CC-POS enables us to study directly the differences in risk 
factors between a person with COVID-19 and a control person 
without respiratory symptoms. Thus, in this analysis, all risk 
factors that increase the risk of COVID-19 (some of which 
will also be risk factors for other respiratory diseases) will be 
seen to differ between cases and controls. Comparison CC-
NEG enables us to directly assess risk factors for the mixture 
of other respiratory pathogens (e.g., influenza virus and rhi-
novirus) that could be causing symptoms similar to those of 
COVID-19.
Critical Reflections on the Interpretation of  
Case–Control Studies with Accompanying 
Persons as Matched Controls
The use of friend controls leaves the choice of the con-
trol to the case and not to the investigator (see pp. 119–120 
in Ref 19). Friend controls may be quite similar to the cases, 
which is an intended benefit of matching. However, they may 
have some possible inherent biases (pp. 119–120 in Ref 19), 
for example, popular persons and extroverts are more often 
mentioned as friends. We should stress that the problem is not 
that the cases and controls are made similar—this problem 
applies to all matched case–control studies and is addressed 
by taking the matching into account in the analyses.18 Rather, 
the problem is that they may be made similar in ways that the 
investigator cannot control, and certain types of persons might 
be more valued to be named as friends.
A second issue is that the accompanying persons of 
the test-positives in the CC-POS comparison may be as yet 
asymptomatic carriers of SARS-CoV-2. A common reflex 
might be to want to know this and to remove these persons 
from the analysis. However, apart from involving logistically 
difficult additional testing of the accompanying persons, it 
is not necessary. This is explained in detail in eAppendix C; 
http://links.lww.com/EDE/B716. Briefly, the studies are based 
on the source population which would come for testing if they 
develop symptoms; the cases are people who have actually de-
veloped symptoms and come for testing. The controls should 
be a sample of the source population which generated the 
cases.20,21 Because the accompanying persons came with their 
index person for testing, it is reasonable to assume that they 
would also have come for testing at the same facility if they 
had developed symptoms.
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Random Sampling From Country-wide General 
Population Healthcare and Other Databases
In regions or countries where all healthcare activities are 
registered (prescriptions, hospitalizations, test results, etc.) in 
digital databases, it may be possible to use a different type 
of control group, constituting a control population randomly 
sampled from the region or country as a whole. While analy-
ses based on existing databases may lack the immediacy and 
flexibility of point-of-care data collection of persons who are 
tested, the advantage is that data are recorded prospectively in 
past time, and the epidemic can be analyzed, and reanalyzed, 
in its several stages (e.g., in relation to the implementation of 
social distancing and lockdowns).
The analysis of the COVID-19 epidemic would start 
with recorded data of test-positives and test-negatives for 
SARS-CoV-2 in the total administrative population of a 
country or region. While this limits information to healthcare 
data that are registered at a particular point in time, an advan-
tage is that healthcare data that have been registered before 
(e.g., pre-existing diseases and prescriptions, prior hospi-
talizations etc.), can be added, as well as other data such as 
data on crowding, income, level of education, etc., from other 
databases.
A single control group can be used for both CC-POS and 
CC-NEG (see Figure 2). This allows one to randomly sample 
several times as many controls as there are test-positives and 
test-negatives combined. For efficiency purposes, the cases 
and controls, as well as the random population control might 
be limited to an age bracket, say age 15–74, as there will be 
few symptomatic SARS-CoV-2 cases below age 15, and per-
sons above age 75 may not be tested nor hospitalized. Age and 
sex matching are undesirable in the context of COVID-19 as 
these may be determinants of infection and disease course. It 
is always possible to stratify on age and sex, as the numbers 
will be sufficiently large. Matching on being alive at the index 
date of the cases (i.e., the date of testing) might be consid-
ered; however, this might be replaced by a control group that 
is composed of persons being alive in the middle of the month 
in which persons were tested.
It might be objected that we use two different control 
groups for one case group, which is often frowned upon, be-
cause if the findings with the different control groups are dif-
ferent, the investigator has to make a judgment call about the 
most appropriate control group (see pp. 121–122 in Ref 19) 
However, in interpreting, the combination of the TND with 
population control groups neither is really the correct one, as 
both point to a different contrast. This can be learned from 
a test-negative case–control study on urinary tract infection 
with antibiotic-resistant bacteria in contrast to infections with 
sensitive bacteria, with added population controls to both 
groups.10 In this study, male gender proved a strong risk factor 
for antibiotic resistance in the test-negative design, while fe-
male gender was a strong risk factor for urinary tract infections 
in comparisons with the population. This seems like a revers-
ing of usual risk factors, but is logical because men generally 
only acquire urinary tract infections at older ages, subsequent 
to prostate or other pathology which also puts them at risk of 
acquiring resistant bacteria.10 This analysis and reasoning are 
explained in eAppendix D; http://links.lww.com/EDE/B716, 
which shows how the triangulation of the test-negative design 
with population controls leads to identifying the right causal 
pathways.
Other Population Control Groups
Many alternatives for population control selection are 
possible, depending on the situation in different regions or 
countries. Some of these other options will be closer to the 
flexibility of the accompanying-persons control groups, and 
FIGURE 2. Test-negative design and case-control 
studies with random population controls.
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others will be closer to the advantages of using existing data-
bases. The appropriate approach will depend on local consid-
erations. For example:
 ‒Records from General Practitioner databases (e.g., in 
the United Kingdom, in some regions in Italy or Spain), 
or third-party payers and insurers (Medicare, Medicaid, 
health maintenance organizations in the United States), 
which will also allow for database-centered research.
 ‒If patients are presenting in a special setup organized by 
groups of general practitioners (GPs) (e.g., coronavirus 
testing sites managed by several GP practices where 
patients are referred for testing), control persons may be a 
sample from these general practices; this sample could be 
matched to the practice of the referring GPs, or weighted 
according to the size of the referring GP practices. This 
might facilitate the collection of specific new information 
relevant to local situations in individual practices (e.g., 
the use of local sports facilities).
 ‒If patients present to outpatient clinics or hospital depart-
ments, a control group of non-respiratory out- or inpa-
tients might be constructed to represent the catchment 
population of the hospital; such patient controls used to 
be common in pharmacoepidemiology.22
Critical Reflections on the Choice of Population 
Controls
It is imperative to consider to what extent the test-pos-
itives and test-negatives from a TND are representative of all 
cases in the general population, that is, whether the general 
population can really be seen as the source population for the 
tested persons. There are two considerations: patient selection 
and doctor’s preferences.
Patient Selection
Not all diseases present equally to healthcare facilities. 
In countries with universal access to healthcare and relatively 
standardized care, it is likely that, for example, almost all solid 
cancers (colon, lung, etc.) with onset before age 70 will ul-
timately be diagnosed and recorded. That is not the case for 
self-limiting diseases such as influenza-like illnesses or head-
ache, with which many persons will just stay home. Only per-
sons who worry or have more severe symptoms will present 
themselves to a primary care service. Still, in a country with 
universal access to relatively standardized care, the types of 
person who present themselves at several points of care will 
be roughly similar, and if testing is done for SARS-CoV-2, 
test-positives and test-negatives can be seen as drawn from the 
same underlying general population.
The type of person that is tested may differ between 
countries, however. During the initial wave of COVID-19 in 
February–March in Europe, testing for persons with minor 
symptoms was available in Germany; in The Netherlands, only 
persons with symptoms that were sufficiently severe to require 
hospitalization were tested. Because these were country-wide 
measures, in both countries, the general population may be 
seen as the source population. In this context, it should be 
noted that if (self) selection is based only on severity of di-
sease, this will not create a bias in itself within one country.
Problems only arise if there are other factors which 
affect presentation for testing, given a particular level of 
symptoms. For example, consider private healthcare facili-
ties that are only accessible to individuals who can afford 
them (these facilities exist in many guises, from standard pri-
vate health care coming as an employee benefit to facilities 
only available to the very rich). A comparison of the test-pos-
itives and test-negatives from such facilities with a general 
population control group may not be warranted, because of 
inherent differences in socioeconomic status, medical care, 
and lifestyle. Among persons tested in private facilities, both 
test-positives and test-negatives are, for example, unlikely 
to live in very overcrowded conditions. Thus, a better con-
trol group, representing their own source population, might 
consist of other persons (or patients) who make use of the 
same healthcare facilities. This means that one may not be 
able to study all of the causes of the disease (e.g., if pov-
erty is an underlying cause, but no one who accesses these 
healthcare facilities is low income). Also, if we suspect that 
there are differences in access to testing for persons with 
very mild symptoms or without symptoms (depending on 
type or health insurance or wealth), but few such differences 
for severe disease, then one might restrict the analysis to the 
subgroup of tested individuals with more severe sympto-
matic disease.
Doctors’ Preferences
Even in settings with relatively standardized care, there 
might be variation in testing strategies for a new disease like 
COVID-19 between (primary care) practices. The existence 
of physician preference has been studied in different coun-
tries.23 Physician’s preference can be based on a different 
interpretation of the literature on topics where there is not 
yet consensus, or on implicit biases (regarding age, sex, and 
ethnicity). If this is suspected to have been the case, it might 
be better to select population controls from the GP practices 
of the individuals who underwent testing—and to approach 
this in the analysis as a form of matching. Matching by GP 
practice would, however, limit the ability to compare between 
catchment areas and lead to loss of information about regional 
differences. Once again, restricting the analysis to patients 
with severe disease (whether test-positive or test-negative) 
may suffer less from self-selection and testing preference by 
doctors. An analysis according to severity can also be added 
as a sensitivity analysis.
DISCUSSION
An ideal approach for identifying risk factors for 
COVID-19 would involve random or representative popula-
tion sampling.3 However, in the surveillance efforts that are 
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being developed when an epidemic is unfolding, population-
based testing often is limited by laboratory capacity (i.e., due 
to unprecedented demands for reagents and trained techni-
cians), funding, and political will. The first thoughts of deci-
sion makers are to facilitate testing for people with symptoms 
who became ill recently, either to isolate, or to know which 
treatment trajectory is necessary if symptoms worsen.1, 2
The situation with COVID-19 remains urgent in many 
parts of the world, and it is important that the best possible 
use is made of information collected in the process of wide-
spread testing of symptomatic persons. Therefore, there are 
research and public health benefits in employing a test-neg-
ative case–control design, combined with case–control stud-
ies with population controls added to it. Still, such collection 
of information has to be as unburdensome as possible, in 
order not to disturb the primary medical aim: to test people 
for their own benefit and for controlling the epidemic. The 
proposed data collection can be done with a minimal extra 
effort, it would roll along with the epidemic, and it can po-
tentially yield important information at much less cost, and 
with greater ease, than doing genuinely random population 
repeated sampling and testing. In situations where extensive 
databases exist, data will have been collected as the epidemic 
unfolded, and then kept frozen in time in the databases. This 
allows investigators to return to the data and evaluate the 
course of the epidemic with new hypotheses. At the time of 
this writing, several efforts are underway to set up collec-
tions of types of questions and data of interest to study the 
COVID-19 pandemic.24, 25
Adding general population controls yields linked case–
control studies (the TND, CC-POS, and CC-NEG) and creates 
a triangulation situation17 for inferences about local as well as 
general factors that drive the pandemic. Follow-up of test-pos-
itives or test-negatives and other additional strategies will lead 
to better understanding of the course of the disease. In partic-
ular, follow-up starting from a test-negative design of acute 
disease may be a good starting point to provide information on 
the degree and duration of protection from (re)infection con-
ferred by having had a SARS-CoV-2 infection previously and/
or specific antibody titers, because such studies might need 
exact matching on date and place of testing.26 Finally, having 
an infrastructure for a test-negative design already established 
in different settings may be a valuable base to evaluate the ef-
fectiveness of interventions such vaccines when they become 
available, or other measures to limit transmission.
The combined test-negative and population-based 
case–control design may be useful, not only for recurrent 
waves of this epidemic or other epidemics, but also to study 
causes of nonepidemic diseases, in circumstances where a 
test-negative design would have advantages but in which its 
inferences could be strengthened by comparing with popula-
tion controls.
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